Health2Sync, a digital health startup company, and Sanofi, a pharmaceutical company based in France, have partnered to bring the digital solutions for the management of insulin to Japan.
According to the reports, both companies are working together to develop the digitalized features on the insulin in Japan, which also includes the connected caps for the titration alerts and insulin. The company ‘Health2Sync’ has a mobile health app that is currently being used by around 290,000 patients in Japan.
According to a study conducted by the Japan Diabetes Clinical Data Management Study Group, the mean HbA1c level tends to grow among people living with diabetes mellitus. The study also noted that the patients in Japan are receiving an average of 14.8 units of the baseline insulin with a 7.8% HbA1c level, and it is suggesting that, the basal insulin dose might be further optimized through proper approaches.
Both Sanofi and Health2Sync are claiming that, their digital solutions are going to provide help in improving insulin management among healthcare providers and patients with diabetes in Japan. This new partnership emphasises the ambition of the companies to realise a more comprehensive management of chronic diseases through digital solutions.
The companies are still planning to extend their partnership to bring the digital therapeutic solutions to healthcare professionals and patients across Japan and several other markets in the world.